VIGADRONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIGADRONE (VIGADRONE).
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
| Metabolism | Minimal hepatic metabolism; primarily excreted unchanged in urine. |
| Excretion | Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%. |
| Half-life | Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days. |
| Protein binding | Protein binding: <20%; primarily binds to albumin; low binding minimizes drug interactions. |
| Volume of Distribution | Volume of distribution: 0.8 L/kg; indicates extensive tissue distribution, particularly in brain and cerebrospinal fluid. |
| Bioavailability | Oral bioavailability: >80% for tablets; near 100% for oral solution due to rapid absorption. |
| Onset of Action | Oral: 1-2 hours for peak plasma concentration; clinical anticonvulsant effect occurs within 1-2 weeks due to adaptive mechanisms. |
| Duration of Action | Duration: 6-8 hours per dose based on half-life; clinical effect persists 24 hours due to sustained GABA-T inhibition, requiring once or twice daily dosing. |
| Molecular Weight | 129.16 |
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR 30-50 mL/min: 500 mg twice daily; GFR <30 mL/min: 250 mg once or twice daily; ESRD on dialysis: not recommended. |
| Liver impairment | No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment. |
| Pediatric use | Infants (1 month to 2 years): 25-50 mg/kg/day divided twice daily; Children (2-16 years): 25-50 mg/kg/day divided twice daily; maximum 3 g/day. |
| Geriatric use | Initiate at lower dose (e.g., 250 mg twice daily) due to age-related renal decline; titrate slowly; monitor renal function. |
| 1st trimester | Associated with increased risk of major congenital malformations, particularly neural tube defects, cleft palate, and hypospadias. Risk of major malformations is approximately 2-3 times baseline. Use only if other treatments fail. |
| 2nd trimester | Continued risk of congenital anomalies and adverse fetal outcomes. May cause fetal growth restriction and neurodevelopmental delays. Use only if benefits clearly outweigh risks. |
| 3rd trimester | Risk of neonatal hemorrhage due to vitamin K deficiency and early infancy sedation/withdrawal. May cause persistent pulmonary hypertension. Monitor neonate for coagulopathy and withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for VIGADRONE (VIGADRONE).
| Placental transfer | Crosses placenta readily; achieves fetal plasma concentrations similar to maternal levels. Documented in animal and human studies with evidence of fetal tissue accumulation. |
| Breastfeeding |
■ FDA Black Box Warning
Permanent bilateral concentric visual field constriction and other vision loss; risk increases with cumulative dose and duration. Not recommended unless benefit outweighs risk.
| Serious Effects |
Hypersensitivity to vigabatrin or any componentUncontrolled or severe renal impairment (CrCl < 30 mL/min)Pre-existing visual field defects or other irreversible vision lossAcute intermittent porphyria
| Precautions | Vision loss (monitor ophthalmologic exams at baseline and every 3 months), MRI signal abnormalities (T2 hyperintensities in basal ganglia/thalamus), suicidal ideation, withdrawal seizures (taper dose), somnolence/fatigue. |
| Food/Dietary | No significant food interactions reported. However, avoid alcohol as it may exacerbate CNS depression and drowsiness. |
Loading safety data…
| Vigabatrin is excreted in human milk; relative infant dose estimated at 1-3% of maternal weight-adjusted dose. Cases of infant drowsiness, poor feeding, and hypotonia reported. Benefits of breastfeeding generally outweigh low risk, but monitor infant for sedation and adequate weight gain. If infant shows signs of toxicity, consider alternate therapy. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Major congenital malformations, including neural tube defects, cleft palate, and cardiac anomalies, with a dose-dependent risk. Second/third trimester: Fetal growth restriction, neurodevelopmental delay, and neonatal withdrawal symptoms. Risk is highest with polytherapy and doses >1000 mg/day. |
| Fetal Monitoring | Baseline and serial fetal ultrasounds for anomaly detection; regular monitoring of maternal liver function, complete blood count, and visual fields (due to risk of visual field defects). Neonatal monitoring for sedation, poor feeding, and withdrawal symptoms after delivery. |
| Fertility Effects | No significant adverse effects on fertility have been reported in animal studies; human data limited. Hormonal contraceptive efficacy may be reduced due to CYP450 enzyme induction, requiring non-hormonal backup methods. |
| Clinical Pearls | Vigabatrin is an irreversible GABA-transaminase inhibitor used for infantile spasms (West syndrome) and refractory complex partial seizures. Monitor for vision loss due to progressive and permanent bilateral concentric visual field constriction; requires ophthalmologic evaluation at baseline and every 3 months. Titrate slowly to mitigate CNS depression. Drug levels are not routinely monitored. Abrupt discontinuation may precipitate withdrawal seizures. |
| Patient Advice | This medication can cause permanent vision loss; you must have eye exams before starting and every 3 months during treatment. · Report any changes in vision, such as blurring, tunnel vision, or difficulty seeing at night, immediately. · Do not stop taking this medicine suddenly, as it may cause seizures; follow your doctor's instructions for tapering. · Avoid driving or operating heavy machinery until you know how this drug affects you, as it may cause drowsiness or dizziness. · Inform all healthcare providers that you are taking vigabatrin, as it can interact with other medications. |